Ovarian Cancer

Tumor BRACAnalysis CDx is a CE marked companion diagnostic tumor test for ovarian cancer patients. This test can detect up to 50% more patients with mutations in the BRCA1 and BRCA2 genes. BRCA mutation analysis is essential in ovarian cancer patients to identify the subset of women who are most likely to benefit from PARP inhibitors.